Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2020-12-16 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2020-12-16 English
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202 Phase 2a study in Metastatic Pancreatic Cancer
Investor Presentation Classification · 98% confidence The document is explicitly identified as a 'FORM 6-K' filed with the 'SECURITIES AND EXCHANGE COMMISSION' for the month of December 2020. A Form 6-K is a report filed by foreign private issuers to report material information not required to be reported in a 20-F. The text mentions that a presentation used in connection with a KOL webinar is furnished as an exhibit, and a press release is also filed as an exhibit. The content itself is a detailed presentation (slides) discussing clinical study results (COMBAT/KEYNOTE-202) related to CXCR4 inhibition in pancreatic cancer, featuring KOLs. This structure—a Form 6-K filing that primarily contains an Investor Presentation (IP) and related press release—is common. Since the core content provided is a detailed presentation intended for investors/KOLs discussing strategy, financials (clinical trial data), and market position, the most appropriate classification for the *attached material* is Investor Presentation (IP). If the document were just the cover page announcing the filing, RPA or RNS might apply, but since the full presentation content is included, IP is better. However, the filing itself is a regulatory filing (6-K). Given the options, and recognizing that the content is a detailed presentation, IP is a strong candidate. But, since the document is a formal SEC filing (Form 6-K) that incorporates other materials, and it doesn't perfectly match the comprehensive definitions of 10-K or IR, it falls under general regulatory reporting. In many databases, Form 6-K submissions containing investor presentations are often categorized based on the primary purpose of the included material. Since the content is a detailed presentation about clinical data and strategy, 'Investor Presentation' (IP) is the best fit for the substance. If IP were not available, RNS (Regulatory Filings) would be the fallback for a 6-K.
2020-12-16 English
Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202 Phase 2a study in Metastatic Pancreatic Cancer
Investor Presentation Classification · 95% confidence The document is a regulatory filing notification to the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 16/12/2020. The key content states: "Attached hereto is a report on *Presentation for KOL webinar to discuss final results from COMBAT / KEYNOTE-202 Phase 2a study in Metastatic Pancreatic Cancer*" followed by the filename "*KOL_Webinar_16-Dec-2020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of an investor presentation or material related to clinical study results, rather than the presentation itself. Since it is a presentation material being announced, the most appropriate classification is Investor Presentation (IP). However, given the context of a KOL webinar presentation being attached, it strongly aligns with the content of an Investor Presentation (IP). If it were just a brief notice stating the report is available, RPA would be considered, but this document contains regulatory headers and details about the attached presentation content, making IP a better fit for the subject matter being announced.
2020-12-16 English
6-K
Regulatory Filings
2020-12-16 English
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' as a 'REPORT OF FOREIGN PRIVATE ISSUER'. Form 6-K is typically used to report material information that a foreign private issuer is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. The content is a press release announcing final results from a clinical study (Phase 2a COMBAT/KEYNOTE-202) and includes financial/operational updates (planning to meet with regulatory authorities, hosting a KOL webinar). While it contains detailed financial/clinical results, the primary filing mechanism here is the Form 6-K, which serves as a general regulatory disclosure vehicle for foreign issuers. Since 'Form 6-K' is not explicitly listed, the closest general category for mandatory regulatory disclosures that don't fit 10-K, ER, or IR is 'Regulatory Filings' (RNS). However, given the context of a major clinical trial result announcement, it often functions similarly to an Earnings Release (ER) or an Investor Presentation (IP) in terms of content focus, but the structure is dictated by the 6-K filing. In the provided schema, RNS is the best fit for miscellaneous regulatory filings that don't match the specific report types (like 10-K, IR, ER). Since this is a formal SEC filing (6-K) containing material information, RNS is the most appropriate catch-all for non-standard SEC forms.
2020-12-16 English
Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations (Periodic and Immediate Reports of Foreign Corporation) 5761-2000, referencing the Israel Securities Authority and the Tel Aviv Stock Exchange. Crucially, the text states: 'Attached hereto is a report on *Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)*' and references a PDF file. This structure—a brief announcement stating that a specific report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 (The 'MENU VS MEAL' Rule). Although the content relates to clinical trial results, the document itself is the notification of publication, not the full report or an earnings release.
2020-12-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.